Cognition Therapeutics
Pittsburgh, US · Founded 2007 · 29 employees on LinkedIn · 5 known investors
Find your way into Cognition Therapeutics
58 people in our graph share verified history with the Cognition Therapeutics team — schools, employers, funds. One of them is your warm intro.
Yusill Scribnerunlockedknows Susan Catalano · together at Barnard College
×11knows the team · via Barnard College
Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
Founders & leadership
Cognition Therapeutics was founded in 2007 by Susan Catalano and Susan Catalano, Ph.D..
SC
Susan CatalanoinCo-Founder, Chief Science Officer & Member of Board of Directors2007–2022Susan Catalano is a biopharmaceutical executive with 25 years of experience in drug development and financing across small molecule and gene therapy programs. She has founded and taken companies to IPO, raised over $200 million across private and institutional funding sources, and led development of therapies targeting neurological and oncologic indications.
SC
Susan Catalano, Ph.D.Co-founder
LR
Lisa RicciardiinChief Executive OfficerRicciardi joined the company in 2019 after serving as CEO and consultant at Suono Bio and as a retained executive at BioBusiness Links, and she spent 2020 as an executive in residence at Columbia Technology Ventures. She has held public board director roles at biopharmaceutical companies in the US and internationally since 2007.
HS
Harold SaffersteinNamed on SEC filing
Board
NJ
Nada JainBoard director
FH
Franz HeftiBoard director
RG
Robert GailusBoard director
MB
Mark BreedloveBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$27.5M disclosed across 5 rounds · 2014–2018
▶$1.6MraisedNov 2018 · 28 investors · BiotechnologyRule 506(b)
▶$1.6MraisedNov 2018 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Irwin ScherDirector
- Robert GailusDirector
- Mark BreedloveDirector
- Aaron FletcherDirector
- Susan CatalanoExecutive Officer, Director
- Stephen SandsDirector
- Peggy WallaceDirector
- Kenneth I. MochExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $1.6M
- Proceeds to insiders
- $665K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedMar 2018 · 31 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMar 2018 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron FletcherDirector
- Peggy WallaceDirector
- Kenneth I. MochExecutive Officer, Director
- Irwin ScherDirector
- Robert GailusDirector
- Mark BreedloveDirector
- Susan CatalanoExecutive Officer, Director
- Stephen SandsDirector
- Offering amount
- $5M
- Amount sold
- $2.4M
- Minimum investment
- $1K
- Proceeds to insiders
- $575K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJan 2017 · 50 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJan 2017 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peggy WallaceDirector
- Aaron FletcherDirector
- Mark BreedloveDirector
- Robert GailusDirector
- Susan CatalanoExecutive Officer, Director
- Kenneth MochExecutive Officer, Director
- Irwin ScherDirector
- Offering amount
- $6.5M
- Amount sold
- $4.2M
- Minimum investment
- $1.3K
- Proceeds to insiders
- $937.5K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMar 2016 · 41 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMar 2016 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nada JainDirector
- Aaron FletcherDirector
- Harold SaffersteinExecutive Officer, Director
- Mark BreedloveDirector
- Franz HeftiDirector
- Robert GailusDirector
- Susan CatalanoExecutive Officer, Director
- Irwin ScherDirector
- Offering amount
- $4.5M
- Amount sold
- $3.5M
- Minimum investment
- $647
- Proceeds to insiders
- $280K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.8MraisedJul 2015 · 56 investors · BiotechnologyRule 506(b)
▶$15.8MraisedJul 2015 · 56 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nada JainDirector
- Franz HeftiDirector
- Harold SaffersteinExecutive Officer, Director
- Robert GailusDirector
- Susan CatalanoExecutive Officer, Director
- Mark BreedloveDirector
- Offering amount
- $16.6M
- Amount sold
- $15.8M
- Minimum investment
- $3K
- Proceeds to insiders
- $305K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $360.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $224K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $222K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $298.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $142K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $198.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Cognition Therapeutics do?
- Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
- Who founded Cognition Therapeutics?
- Cognition Therapeutics was founded by Susan Catalano, Susan Catalano, Ph.D. in 2007.
- Who are Cognition Therapeutics's investors?
- Cognition Therapeutics's investors include 3E Bioventures Capital, Atlanta Technology Angels, Houston Angel Network, iNetworks, Dolby Family Ventures.
- How much funding has Cognition Therapeutics raised?
- Cognition Therapeutics has disclosed $27.5M raised across 5 rounds.
- Where is Cognition Therapeutics headquartered?
- Cognition Therapeutics is headquartered in Pittsburgh, US.